Patent Application
20230329616
The present invention provides methods for performing cardiac mapping procedures to provide the cardiac electrophysiology therapy (EPT); electrophysiology catheters, cardiac implantable devices and cardiac implantable leads.
EP 1233716 B1 discloses a catheter which has a helical electrode member. The effective length and diameter of this electrode member can be adjusted by actuating a stylet which runs through a hollow, flexible body of the catheter. The stylet runs through hollow, flexible body before exiting the body at aperture. The stylet re-enters the body of the catheter through aperture and in to anchor member.
US 2001/0039413 A1 describes a steerable catheter. The catheter comprises a wire housed within a sheath which is formed of a shape-retentive and resilient material having a curved shape at its distal end. An operator can adjust the shape and radius of curvature of the distal end region.
US 2005/0177053 A1 shows as system for perform an ablation procedure. The handle shown in the system has a safety switch for shutting down the RF generator which delivers current to the heart via the catheter.
WO 03/089997 A2 discloses a method and apparatus for control of ablation energy in an electrophysiology catheter. It does not provide means for selective stimulation of the heart. It uses resistors to form a virtual electrical null point (average) for unipolar electrogram channels. The resistors are fixedly connected and cannot be switched.
U.S. Pat. No. 5,357,956 A discloses an apparatus for monitoring an endocardial signal during ablation with the same single electrode. A switch switches either the ablation device or the monitor to the single electrode.
DE102018133630.6, EP19180033.3 and PCT/EP2019/086922 disclose a cardiac electrostimulation device, specially configured to channel current out from the heart via a resistor connected to a switch during an electrophysiology procedure which involves cardiac ablation.
JP5880512B2 discloses a method of forming a semiconductor device member forming liquid, semiconductor device member, and semiconductor light emitting device. According to the JP5880512B2 the liquid semiconductor is not suitable for use in a biological environment.
US20130189823A1 relates to electrically active devices (e.g., capacitors, transistors, diodes, floating gate memory cells, etc.) having dielectric, conductor, and/or semiconductor thin layers with smooth and/or dome-shaped profiles and methods of forming such devices by depositing or printing (e.g., inkjet printing) an ink composition that includes a semiconductor, metal, or dielectric precursor.
The modern era of cardiac electrophysiology started in 1986 with the radio frequency ablation. Different forms of energy like cryoablation, laser, ultrasounds, have been added since then, all of them are world wide in use nowadays.
So far, the ablation is the only ways to treat a cardiac arrhythmia by further scarring the already damaged arrhythmogenic tissue known as arrhythmic substrate, in an intent to stop the arrhythmia and/or render it non reproducible (the patent literature cited above under the description of the related art represents merely a selection).
The ablation procedures not exempted from serious complications due to their aggressive nature, typically involving destruction of the heart tissue, are far from being effective specially in patients with common arrhythmias such as atrial fibrillation, atrial tachycardias and ventricular arrhythmias as depicted by the high rate of recurrences and even redo procedures in most EP-labs around the world.
Exceeding the prior art by far, the invention opens a not yet explored realm of cardiac electronics. The invention discloses a method that provides for the first time the electronic mechanisms of an arrhythmia induction, maintenance and termination at intimate-cellular level at the arrhythmic substrate, that restores the electronic properties of the arrhythmic substrate by channeling current out from the substrate, by inking it in or both, in an intent to stop an arrhythmia and render it non reproducible; a cardiac electrophysiology device and a versatile catheter device for the electrophysiology therapy. The innovative method involves cardiac mapping and electronic cardiac mapping of the arrhythmic substrate. The innovative method involves three dimensional cardiac mapping.
The solution of the problem is described in the independent claims. The dependent claims relate to further improvements of the invention.
The human heart is a very complex organ, which exerts efficient and synchronised muscle contractions when the electrical current flows properly throughout it.
To provide a normal heartbeat, a current flow path is set from the sinoatrial node down to the atrioventricular node and then throughout the ventricles along the specific His-Purkinje system when a naturally occurring voltage applies to the heart. The atria contract first, followed by the ventricles. This is essential for the proper functioning of the heart. The sequence of these electric events along this current path is called heart depolarisation. The heart depolarisation is commonly followed by the heart repolarisation. Despite the fact that the repolarisation was widely depicted, there is no clear evidence to which current path is it associated, in other words how does the current exit the heart before, or keep traveling throughout it to the next depolarisation. The atrial repolarisation has a tiny expression on the surface ECG so far not yet properly characterised. Contrary, the ventricular repolarisation has a robust surface ECG expression, known as the terminal phase. To date, there is no consistent data that can derived from prior art to sustain that the terminal phase actually electromagnetically supports the next depolarisation. An existing anatomical model of the heart, the so-called myocardial band may allow a novel theory according to which repolarisation can electromagnetically induce the atrioventricular node to set the current path required to the next depolarisation-repolarisation sequence, commonly electrophysiologically depicted by the H-V potentials recorded with a catheter suitable placed into a beating heart. The phenomenon typically related to the presence of an induction coil in physics, has never been related to the anatomy, nor to the twisting mechanical performance of a beating heart until now. The theory according to which the repolarisation electromagnetically reloads the heart to allow at least in part the next depolarisation is new over the prior art, is not confined to this invention and may be further on explained in separate embodiments.
When a natural occurring voltage applies to the heart in vivo, a resultant improper or impaired flow of the electrical current throughout the heart disrupts the heart's proper function and causes or represents a cardiac arrhythmia. Arrhythmias can present as the electrical current enters the heart from another regions to initiate and maintain abnormal rhythms, what is called an ectopic or focal arrhythmia. Another possibility is, when current circulates repetitively in a closed circuit involving various amounts of heart regions, what is called a reentrant arrhythmia. In both situations, that heart region responsible for the initiation and/or maintenance or the arrhythmia defines the arrhythmic substrate. The arrhythmias are paroxysmal, incessant, persistent or long lasting persistent and permanent.
In the cardiac electrophysiology, it has become state of the art that the signals associated with an arrhythmia have lower amplitude when compared to the normal signals not associated with an arrhythmia, that they generally anticipate or follow the normal signals, such as in case of the so called late potentials, and that they typically exhibit a fragmentation pattern and/or a longer duration in comparison with the normal signals not associated with an arrhythmia. An explanation of this phenomenon has not yet been provided. It is the scope of the invention to state that the genesis of such signals at the level of the arrhythmic substrate (near field signals) or remote from it (far field signals) is truly explained by the electronic behaviour of the arrhythmic substrate. Furthermore, it is not the scope of the invention to provide a detailed analysis of the cardiac signals associated with an arrhythmia as they are a surrogate or the result of the electronic behaviour of the arrhythmic substrate and not the cause of it.
The invention postulates that an arrhythmia occurs whenever the variation of the voltage (V) and the variation of the current (I) have opposite signs at the level of the arrhythmic substrate, id.est. whenever the arrhythmic substrate exhibits negative differential resistance (NDR). In other words, according to the invention, the arrhythmia occurs whenever the VI relationship at the level of the arrhythmic substrate is confined to at least one NDR domain (such as 1-2 domains at the N curve or 3-4 domains at the S curve), as depicted in
To study the mechanism of an arrhythmia in the EP-lab, pharmaceutical manipulation is used and/or electrical stimuli are typically applied from en external voltage source, called stimulator, via catheters suitable positioned within the heart, typically in contact to the arrhythmic substrate. These manoeuvres establish new current paths inside the heart that create a mismatch between the voltage and the current within the arrhythmic substrate thus allowing induction, maintenance of an arrhythmia as well as the termination of the arrhythmia as the mismatch ceases. The invention considers that the mismatch implies that voltage and current vary in opposite directions within the arrhythmic substrate resulting in a negative value of the instantaneous differential resistance recorded topically at the level of the arrhythmic substrate by mapping the substrate. Common pharmacologic and/or stimulation manoeuvres may reveal phenomena such as jump, Wenckebach, entrainment and overdrive at the level of the arrhythmic substrate, all of these features already known in the prior art, but so far not yet intimately explained as in the light of the electronic properties of the arrhythmic substrate. The mismatch induced in the EP-lab is deemed further on to simulate a natural occurring condition that involves the induction and the maintenance of an arrhythmia. According to the degree of the mismatch induced, a variable amount of the arrhythmic substrate may be revealed; usually in the EP-lab and by using common pharmacologic and/or electric stimulation manoeuvres, one may not want to reveal an arrhythmic substrate that exceeds the extent of the arrhythmic substrate related to the clinical arrhythmia.
However, the arrhythmic substrate may be sometimes defined and treated in the absence of the arrhythmia itself, given that the heart recognises a hysteresis-like electrophysiology behaviour, responsible for sequences of spontaneous initiation, maintenance and even termination of an arrhythmia after an arrhythmia-free time interval or remote from previous arrhythmias.
A first embodiment of the invention relates to a cardiac electrophysiology device and a catheter device adapted for direct tissue electromechanical coupling.
The cardiac electrophysiology device may comprise an active electrode device comprising at least one or at least two active electrodes, a neutral electrode, a resistor connected to the neutral electrode and a second selector switch configured to connect the resistor further to at least one of the active electrodes. According to the setting of the second selector switch (155), a selected active electrode may be connected via the resistor (151) to the neutral electrode (170), forming an electrical current path from the selected active electrode to the patient body. It may further comprise a first selector switch configured to connect a sensor device comprising a voltage (161) and current (162) meters to at least one of the active electrodes. The selector switches may be implemented but not only as semiconductor circuits. The sensor device (160) derives the instantaneous differential resistance from the values provided from 161 and 162 and provides real time output data particularly when the measured value of the instantaneous differential resistance is or turns negative, or is or turns equal or greater than zero during the cardiac mapping. The neutral electrode may be connected to the at least one resistor or the sensor device directly or via at least one selector switch which may be part of the control unit and may be configured to be attached to a patient. The neutral electrode closes the electrical circuit via the at least one electrode from the electrode device. The purpose and the architecture of the electrophysiology device and its connections are unique. For attaching the electrode to a patient, the neutral electrode may have an adhesive surface.
The cardiac mapping, further on referred herein as mapping, typically involves moving of a mapping catheter inside the heart or over the external surface of the heart in electromechanical coupling with the heart tissue by mapping manoeuvres executed from the operating physician directly with his hands over the catheter device (110) that comprises a mapping catheter according to the invention, or indirectly, remote, by commanding a computer connected to a robotic mapping system further on connected to the catheter device (110). Typically, mapping results in a map of a cardiac structure, commonly a three dimensional anatomical map of said cardiac structure typically involving the arrhythmic substrate. The mapping catheter assures the abiotic/biotic interface between the catheter device and the heart. In other embodiments, a mapping catheter localisation system may be provided.
At various points in the heart, a cardiac electrogram (EGM) may be recorded. During the measurement, the dissipation of electrical signals within the heart may be estimated with the aforementioned catheter device.
A control unit (150) may be configured to control the first selector switch (156) and the second selector switch (155) during mapping.
By setting the value of the variable resistor, current can be set up to be channeled out from the heart via at least one electrode at the distal end of the catheter device. The amended current dissipation can be recorded via the sensor device 160 and may be configured to be maximal depending upon the setting of the value of the resistor (either a very low or a very high setting within, but not limited to the proposed ranges, from 0.10 ohm to 2 mega ohm). In whichever case and provided that the first selector and the second selector switch refer to the same selected electrode, the sensor device 160 may be said to work in an unipolar mode. Again, in whichever case and provided that the first and the second selector switch refer to different selected electrodes, the sensor device 160 may be said to work in a bipolar mode. Preferably, the value of the resistor is set high for the bipolar mode, or optionally low for the unipolar mode.
It is possible then, provided the unipolar setting mode of the sensor device to unipolar point by point mapping of the totality of points that form the arrhythmic substrate.
It is possible then, provided the bipolar setting mode of the sensor device to bipolar point by point mapping of the totality of points that form the arrhythmic substrate. Further on, and according to the method disclosed herein in claim 3, it is possible then, by repetitively applying the said method disclosed herein in said claim 3 for each point of the arrhythmic substrate, to map the totality of points that form the arrhythmic substrate to further on provide the electrophysiology therapy to all of them according to the method disclosed further on herein, in claims 4-9.
As aforementioned, the heart exhibits a measurable spontaneous electrical current flow when a voltage applies, that respects a hysteresis behaviour over time.
The invention postulates that, in normal conditions the normal spontaneous electrical activity of the heart prevents the existence of regions within the heart in which a measurable negative differential resistance can be derived and demonstrated by mapping.
Further on, the invention postulates that the spontaneous electrical activity of the heart is altered in case of the existence or coexistence of regions confined to the heart in which the presence of a measurable negative differential resistance (NDR) can be demonstrated by mapping. The alteration may involve a predisposition to develop an arrhythmia, the arrhythmia itself either self limited or persistent, a combination of arrhythmias either self limited or persistent, as well as a complete loss of the spontaneous electrical activity of the heart. Any of these alterations or a combination of them may be reversed by identifying and treating the regions found to have a measurable negative differential resistance (NDR) at mapping, for which the methods and devices disclosed herein in this invention may constitute one first option. The implementation of the nano technologies, the use of now trendy materials such as soluble graphene or bio derivates, but not only, may optimise both the accuracy of the methods and the spatial resolution of the devices disclosed further on, herein.
When the value of the differential resistance measured by the sensor device (160) is or turns negative, and according to the setting of the first selector switch (156), the selective active electrode connected to the first switch (156) may be considered to be approaching the arrhythmic substrate or in electromechanical coupling with the arrhythmic substrate that should be targeted for the electrophysiology therapy (EPT). A floating selective active electrode connected to the first switch (156), provided according to the three dimensional architecture of the mapping catheter during mapping cannot provide a negative value of the measured differential resistance to the sensor device 160; therefore the selected active electrode providing the sensor device 160 with a negative differential resistance value has to be in electromechanical coupling with the arrhythmic substrate and cannot be a floating electrode.
According to the present disclosure the electrophysiology therapy (EPT) implies the ink staining of the arrhythmic substrate, with the electronic ink as disclosed further on, herein below.
Staining inks are tailored in such a way that they are able to resist the immune response, the accidental or not desired blood clotting and viral and/or bacterial colonisation.
The selective active electrode in electromechanical coupling with the arrhythmic substrate may further on be set by mapping manoeuvres and by correspondingly changing the setting of the first selector switch (156), to be the electrode most suitable, according to the three dimensional architecture of the mapping catheter, for the electrophysiology therapy (EPT), preferably, but not limited to one of the tip or central electrodes of the mapping catheter. When the mapping manoeuvres are not sufficient to optimally position the electrode most suitable, according to the three dimensional architecture of the mapping catheter for the electrophysiology therapy, in electromechanical coupling to the arrhythmic substrate, or due to slippage of the mapping catheter at the abiotic/biotic interface, an additional mapping catheter, preferably with another architecture may be optionally employed and suitable positioned directly in electromechanical coupling to the arrhythmic substrate, as previously identified and according to the initial position of the first mapping catheter and the initial setting of the first selection switch (156), to further on be used only for the electrophysiology therapy (EPT). Given the multipolar design of most modern mapping catheters (linear, circular, basket, grid, mesh, orthogonal close unipolar or balloon), a second mapping catheter is usually not needed.
In the usual case that the second mapping catheter is not needed and provided that the setting of the catheter device achieved by mapping manoeuvres did not change by additional mapping manoeuvres or movements of the mapping catheter and that the setting of the selective active electrode connected with the first selector switch (156) did also not change after the first mapping manoeuvres, so that the selective active electrode most suitable according to the three dimensional architecture of the mapping catheter for the electrophysiology therapy is still in electromechanical coupling to the arrhythmic substrate, the electrophysiology therapy (EPT) is provided to the arrhythmic substrate. In the other case when a second mapping catheter is needed, it is used only for directly providing the electrophysiology therapy to the arrhythmic substrate, previously established with the first mapping catheter during mapping.
Most mapping catheters are open irrigated catheters allowing fluid passage from their proximal end to their distal end through their internal lumen, which prevents fluid leakages and is configured to have a proximal and a distal orifice. The proximal orifice is connected via the catheter device with a fluid reservoir, optionally controlled by a mechanical pump which establishes the exact amount of flow to be passed that may further on be set according to the clinical settings of the patient, the type of the arrhythmia and the type of the mapping catheter as well. The distal orifice opens externally when the mapping catheter is not inserted into the body, internally into another body structure before mapping or within the heart or adjacent to the external surface of the heart during mapping.
In the prior art, mapping catheters are commonly flushed with sterile saline, optionally heparinised sterile saline to prevent clot adhesion to the distal end during mapping.
Exceeding by far the prior art, the invention discloses the electrophysiology therapy (EPT) which comprises the passage of a potentiometric or an organic semiconductor staining ink through the lumen of the mapping catheter, the delivery of said staining ink to the arrhythmic substrate and the ink staining of the arrhythmic substrate. The invention postulates that the electrophysiology therapy (EPT) induces a minimal, rather beneficial reduction of the shear and/or stretch stress at the level of the arrhythmic substrate where it applies.
To provide conformity with the arrhythmic substrate, the staining ink may be chosen further on to be lipophilic, oxidised lipophilic or polymeric or to non invasively dissolve into the arrhythmic substrate.
To provide conformity with the arrhythmic substrate, the staining ink may be chosen further on to exhibit magnetic properties. An external magnetic field may be configured to be provided and tailored to provide the electrophysiology therapy (EPT) at the level of the arrhythmic substrate. In the prior art, the magnetic navigation of a magnetic guidable catheter in a magnetic environment applied to a human body as provided by a magnetic navigation system is commonly referred as the navigation of a “small magnetic body”. Exceeding by far the prior art, the invention considers that the electrophysiology therapy (EPT) implies the navigation of the innovative staining ink, that represents a liquid “small magnetic body” in close proximity to the arrhythmic substrate in said tailored magnetic environment applied to a human body. This provides the electrophysiology therapy (EPT) in close proximity to the arrhythmic substrate. This further on provides the electrophysiology therapy (EPT) conformal to said arrhythmic substrate. In other embodiments, a dedicated catheter device containing a small magnetic body and magnetically guidable in said magnetic field independently from the magnetic exhibiting properties staining ink, the liquid small magnetic body is provided and configured for the electrophysiology therapy (EPT). It is obvious for those skilled in the art that the navigation of the small magnetic body towards the arrhythmic substrate and the navigation of the liquid small magnetic body in small amounts as for the EPT in close proximity and conformal to the arrhythmic substrate cannot be simultaneous such as to prevent undesired EPT far away from the substrate and to assure stability at the arrhythmic substrate as well, during the EPT. Furthermore two separate navigation algorithms for a small magnetic body and for the liquid small magnetic body are needed. An adequate release flow rate of the EPT from the ink can through the internal lumen of the catheter device and mapping catheter is provided. A magnetic visualisation of the magnetic staining ink in situ, conformal to the arrhythmic substrate may be provided in a dedicated magnetic field, time remote from the therapy as well.
To provide the electrophysiology therapy (EPT) to the arrhythmic substrate, the electrophysiology device, the catheter device (110) and the control unit (150) may be needed.
The catheter device preferably has a distal end and a proximal end. The distal end may be configured to be attached to a mapping catheter. A flexible shaft (140) connects the distal end and the proximal end. The flexible shaft can be made of a plastic material. The proximal end of the catheter device may be designed to be connectable to a handle for operating the functions and movements of the mapping catheter as well as the functions of the catheter device, the control unit or the sensor device.
The distal end of the catheter device comprises a plurality of electrodes, including tip electrodes, central electrodes according to the geometry of the mapping catheter that may be chosen to be linear, circular, basket, grid, mesh, orthogonal close unipolar or balloon among them. The electrodes of the catheter device can be located around the distal end with a predefined distribution and distance from one electrode to another. Each of the electrodes is connected via a plurality of low resistive wires to a plurality of connectors at the proximal end (130) of the catheter device. The proximal end of the catheter device may have a connecter for connecting the catheter device to a handle (180). The connector may comprise a screw-plug connection for establishing an electrical as well as a mechanical connection. A connection to the ink can is also provided.
The handle for operating the functions of the mapping catheter as well as the functions of the catheter device may have at least one operating element to control the control unit (150). The handle may have at least one electrical connection for connecting the handle to the control unit. Preferably, the electrical connection of the catheter device corresponds to electrical connection of the handle. In one embodiment, the handle can be located in the signal path between the catheter device and the control unit.
The sensor device is connected by the selector switch to at least one of the electrodes which can be the same or another than the electrode connected to the resistor. The configuration of the resistor according to the electrodes and the sensor device is dependent of the measurement task, which has to be executed. In one embodiment, the sensor device is configured to record the voltage and current over time. In other words, the sensor device is able to detect at which time which electrical potential is at a dedicated electrode. In another embodiment, the sensor device can be configured to measure the current channeled out of the heart by one of the electrodes. The catheter device may further comprise a control terminal with a display for controlling the measurement results as well as the chosen settings of the catheter device. The screen can be configured as a touch screen to control the functions of the catheter device or the control unit.
The neutral electrode may be connected to the at least one resistor or the sensor device directly or via at least one selector switch (not graphically displayed) which may be part of the control unit and may be configured to be attached to a patient. The neutral electrode closes the electrical circuit via the at least one electrode at the distal end of the catheter. For attaching the electrode to a patient, the neutral electrode may have an adhesive surface.
The flexible shaft may have several working channels as guide for several tools or electrical, optical or mechanical connections such as low resistive wires. The working channels can also be used as media feed-through for example for liquids. The catheter device may have a diameter from approximately 1 to 5, preferably from 1 to 3 mm.
The flexible shaft may include at least one wire, which can be formed of a super elastic material and can be shaped to bias the flexible shaft as well as the distal end in several orientations. The super elastic wire may be connected to a control element of the handle.
In a second embodiment of the invention, the cardiac electrophysiology device is configured to be an internal compound of a cardiac implantable device, such as a pacemaker (PM), a defibrillator (ICD) or a contractility modulation (CCM) device. All these devices, except CCMs possess pacing functions that according to specific pacing algorithms provide a paced rhythm to the heart by sequentially pacing one or more heart chambers. By adding synchronised non excitatory potentials, CCMs optimise the mechanical response of a paced rhythm of the heart as provided by PMs and ICDs. In order to establish when, if and which pacing algorithm is activated, to create a paced rhythm of the heart, the cardiac implantable devices above mentioned possess sensing functions. The sensing functions, according to specific sensing algorithms can determine if the heart exhibits a spontaneous electrical activity or not, if yes, whichever it might be, if it involves or not an arrhythmia. When the spontaneous electrical activity of the heart is interpreted according to the sensing algorithms to indicate an arrhythmia, the detection specific algorithms are activated in order to characterise that arrhythmia.
The cardiac electrophysiology device may be configured to be an internal compound, optionally be part of the electrical circuitry of a cardiac implantable device (CID) as mentioned below or part of an implantable lead of a CID. The neutral electrode may be configured to be part of the housing of the cardiac implantable device or may be configured to be a floating electrode. The electrophysiology device may be optionally configured to receive input data when an arrhythmia is present, from both the sensing and detection algorithms as of a cardiac implantable device that further on, may be a cardiac pacemaker, defibrillator or a contractility modulation device.
Both sensing and detection algorithms of the cardiac implantable device (CID) below mentioned, provided that it incorporates the cardiac electrophysiology device disclosed herein by the invention as part of its electrical circuitry or part of an implantable lead, may be configured to receive inputs from the sensor device (160) and further on to define an arrhythmia whenever the inputted value from the sensor device represents a negative differential resistance (NDR), as herein depicted below. The inputs may be configured to be the instantaneous measured values provided by the voltmeter (161) and the current meter (162). Preferably, these inputs include the value of instantaneous differential resistance as provided by the sensor device (160) as a result of computing the instantaneous values furnished by the voltmeter (161) and the current meter (162).
Furthermore, the cardiac implantable device (CID) above mentioned, provided that it incorporates the cardiac electrophysiology device as disclosed by the invention may be configured to set and to alter the setting of both the first (156) and the second (155) selector switches of the cardiac electrophysiology device according to a multipolar configuration of at least one of the implantable leads of the CID, which now herein disclosed by the invention. Both the unipolar and bipolar connecting modes of the sensor device (160) may apply, according to the previous description of the sensor device 160 refreshed herein below.
In whichever case and provided that the first selector and the second selector switch refer to the same selected electrode, the sensor device 160 may be said to work in an unipolar mode. Again, in whichever case and provided that the first and the second selector switch refer to different selected electrodes, the sensor device 160 may be said to work in a bipolar mode. Preferably, the value of the resistor is set high for the bipolar mode, or optionally low for the unipolar mode.
The electrophysiology device may be configured to connect the resistor to at least one of the at least two active electrodes, if an arrhythmia is detected according to the detection algorithms above mentioned or when, according to the invention, an arrhythmia is defined whenever the instantaneous value of the differential resistance provided from from sensor device 160 is or turns negative. By setting the value of the variable resistor, current can be set up to be channeled out from the heart via at least one electrode at the distal end of the electrophysiology device. The amended current dissipation can be recorded via the sensor device 160 and may be configured to be maximal depending upon the setting of the value of the resistor (either a very low or a very high setting within, but not limited to the proposed ranges, from 0.10 ohm to 2 mega ohm).
Such therapies can be activated and delivered by CID through the the electrophysiology device and the implantable leads as many times as the arrhythmia presents itself. That involves a repeatedly out-channeling of current out of the heart by setting and changing the setting of the resistor and of first and/or second selector switch until the arrhythmia terminates. The setting and the sequence in which the settings of the resistor and of first and/or second selector switches are changed to prevent the occurrence of an arrhythmia or during an arrhythmia until the arrhythmia terminates may be programmed as part of the conventional programming session of the CID, which disclosed herein above. They may be configured to provide in case of an arrhythmia the maximal current out-channelled out from the heart to terminate that arrhythmia. In further embodiments an innovative design is further needed for the implantable leads of the CID, beyond the frame, but without leaving the scope of this invention.
When the heart beats too slowly or does not exhibit a spontaneous electric activity at all, a so called bradycardia, the cardiac implantable devices like pacemakers or defibrillators provide programmable voltage outputs to the heart which result in electric stimuli that pace the heart to a normal frequency.
When the heart beats too rapidly as during a tachycardia, pacemakers can provide series of programmable voltage outputs, to overdrive that tachycardia, defibrillators can further on deliver electrical shocks to terminate the tachycardia if the previous overdriving algorithms proved to be ineffective. Cardiac contractility devices may temporarily inhibit all their pacing algorithms.
Both overdriving a tachycardia and the deliverance of an electrical shock in an intent to terminate such an arrhythmia are achieved by applying of some increasing external voltages to the heart. It involves a rightwards slippage of the arrhythmic substrate VI relationship along the NDR domain during an arrhythmia in an intent to diminish the current I up to a critical I minimum point 2 or 3 that actually interrupts the arrhythmia.
According to the invention, the rightwards slippage along the NDR domains is directly achieved by primarily decreasing current at the level of the arrhythmia substrate by channeling current out of the heart according to the innovative therapy proposed by the invention, until the arrhythmia terminates. This therapy has less negative impact and less side effects in comparison with the conventional therapies (overdrive burst, ramps and shocks), which known from prior art typically provided by conventional cardiac implantable devices such as pacemakers and defibrillators.
According to the invention, the first and the second embodiments apply to clinical settings, involving both bradycardia and/or tachycardias and do not exclude each other. The decision to choose either one therapy or both, according to whichever of the two embodiments disclosed herein in the invention, is proposed as a joint decision of the patient and the physician.
In the following, the invention will be described by way of example, without limitation of the general inventive concept, on examples of embodiment with reference to the drawings.
The distal end has a plurality of electrodes 121, 122, 123, 124.
The handle 180 has two operating elements 181, 182 to control the function of the catheter or the catheter device. In this configuration, the handle 180 can be configured to control the distal end 120 of the catheter 110 via the operating element 181. The handle 180 can be further configured to trigger different measurement functions of the catheter device, respectively of the control unit or the sensor device via the operating elements 182. The handle 180 can have at least one electrical connection for connecting the handle to the catheter device 110 and a connection to the ink can.
A neutral electrode is connected to the resistor and/or sensor device.
This neutral electrode 170 allows current from the heart 200 of the patient to flow back to the body. For attaching the neutral electrode 170 to a patient, the neutral electrode 170 may have an adhesive surface.
Although the invention has been illustrated and described in detail by the embodiments explained above, it is not limited to these embodiments. Other variations may be derived by the skilled person without leaving the scope of the attached claims.
In addition, numerical values may include the exact value as well as an usual tolerance interval, unless this is explicitly excluded.
Features shown in the embodiments, in particular in different embodiments, may be combined or substituted without leaving the scope of the invention.
Keywords
| Number | Date | Country | Kind |
|---|---|---|---|
| 19180033 | Jun 2019 | EP | regional |
| PCT/EP2019/086922 | Dec 2019 | WO | international |
This application claims the priority of EP19180033.3, filed on Jun. 13, 2019 and PCT/EP2019/086922 filed on Dec. 23, 2019, which claim priority to DE 102018133630.6 filed on Dec. 27, 2018. The entire disclosures of the above applications are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2020/055111 | 5/29/2020 | WO |
